SEROQUEL ARTICLES
FOR $520 MILLION, ASTRAZENECA SETTLES CASE OVER MARKETING OF A DRUG
by Duff Wilson
AstraZeneca has completed a deal to pay $520 million to settle federal investigations into marketing practices for its blockbuster schizophrenia drug, Seroquel, the Attorney General, Eric Holder, said at a news conference Tuesday afternoon. Read more on AstraZeneca's fine here... (pdf format 29.4Kb)
Source: New York Times
Posted: April 27, 2010
WEIGHTY ISSUES IN 2007
By Steven Dubovsky, M.D.
The U.S. epidemic of obesity and diabetes holds special meaning for psychiatrists because their patients seem particularly at risk and because many psychotropic medications have metabolic effects. In October, the Food and Drug Administration mandated changes to the label for olanzapine to warn of its associations with increased levels of glucose, cholesterol, and triglyceride levels. This past year saw several studies clarifying these issues. (pdf format 52.8Kb)
Source: Journal Watch Psychiatry
http://psychiatry.jwatch.org
Published December 28, 2007
AGAIN, HIGHER MORTALITY WITH ANTIPSYCHOTICS IN PATIENTS WITH DEMENTIA
By Allen S. Brett, M.D.
Although antipsychotic drugs are prescribed widely to control neuropsychiatric symptoms in patients with dementia, recent studies suggest questionable efficacy and an association with increased mortality. ... this study gives us yet another reason to avoid antipsychotic drugs in demented patients. [pdf format 22Kb ...]
Published in Journal Watch General Medicine
http://general-medicine.jwatch.org/
October 11, 2007
Astrazeneca
March 2005 - Study finds Seroquel effective and tolerated. (pdf format 21Kb)
AstraZeneca Submits SNDA For SEROQUEL(R) For Bipolar Depression Treatment
http://www.medicalnewstoday.com/medicalnews.php?newsid=35626
Provides information about Astazeneca submitting SNDA for Seroquel.
NAMI [National Association of Mental Illness]
http://www.nami.org/template.cfm?section=About_NAMI
NAMI's Fact Sheet on Seroquel (quetiapine).
New Seroquel Data Supports Benefits in Bipolar Disorder
http://www.medicalnewstoday.com/medicalnews.php?newsid=25058
Article provides informatin on data presented to the American Psychiatry Association about the effectiveness of Seroquel.
The Nations Law Firm | A National Pharmaceutical Litigation Firm
4515 Yoakum Boulevard | Houston, TX 77006-5895 | Telephone: 713-807-8400 / Toll Free: 1-800-269-3050 | FAX: 713-807-8423
Website Administrator ~ Cindy Nations | Website design and maintenance by Lacey Crawford | Site hosted by NCC
